Different SGLT2 inhibitors including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin are approved for the therapy of T2D and have been recently evaluated for their cardiovascular risk profile in clinical trials (Zinman et al., 2015; Neal et al., 2017; Wiviott et al., 2019). Here, SLC5A2 is linked to type 2 diabetes mellitus.